Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11274631 | 0.83 | — | — | |
| SCHEMBL20133522 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ALMNA | |
| SCHEMBL4330349 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ALMNA | |
| SCHEMBL107892 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ALMNA | |
| SCHEMBL23097183 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ASLC7A5 | |
| SCHEMBL585124 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ASLC7A5 | |
| SCHEMBL22760260 | 0.82 | USP2 (0.48) | USP2SLCO1B1TDP1PDE4ASLC7A5 | |
| SCHEMBL19681574 | 0.82 | USP2 (0.48) | USP2SLCO1B1TDP1PDE4ASLC7A5 | |
| SCHEMBL587181 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ASLC7A5 | |
| SCHEMBL15423731 | 0.82 | USP2 (0.65) | USP2SLCO1B1TDP1PDE4ASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | CD74, CD99, CD2 | USP2 1833/4885SLCO1B1 2031/4885TDP1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.